Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-omega-propyl-L-arginine is a synthetic amino acid derivative that functions as a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS). It exhibits significantly lower inhibitory activity against endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS). Primarily used as a research tool, it has been investigated in animal models for its effects on nNOS-dependent physiological and pathological processes, including its ability to block phencyclidine-induced behavioral changes and its hypotensive properties. It is explicitly stated as being for research use only and is not intended for therapeutic or diagnostic use in humans or animals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-omega-propyl-L-arginine.